
LX Bio Pharmaceuticals
Biotechnology pharmaceutical company focused on developing antibody and bacteriophage therapies for unmet medical needs.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
* | N/A | N/A | Series B |
Total Funding | 000k |
EUR | 2021 | 2022 | 2023 |
---|---|---|---|
Revenues | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Lxbio Pharmaceuticals operates in the biotechnology sector with a primary focus on phage therapy, aiming to develop solutions that transform disease treatment and prevention. The company targets a global market, striving to improve the quality of life sustainably. Lxbio's business model involves research and development projects supported by significant investments, such as the recent 6 million Euros from Explorer Investments. This funding aids in expanding their high-value product exports and promoting skilled employment in Portugal. Lxbio is committed to ethical and responsible biotechnological advancements, aspiring to inspire a new era in healthcare. The company ensures data protection and privacy, retaining user information only as necessary for service provision. Keywords: biotechnology, phage therapy, disease treatment, prevention, global market, research, development, investment, ethical, healthcare.